Post Marketing Observational Study to Assess Patient Management Practices and Quality of Life With the Capsules Form of Paricalcitol in the Treatment of SHPT in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis Under Conditions of Usual Clinical Care.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Acronyms CAPITOL
Most Recent Events
- 19 Feb 2014 Biomarkers information updated
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.